Lawyers Selin Sinem Erciyas

Selin Sinem Erciyas

Selin Sinem Erciyas

Gün + Partners

Selin Sinem Erciyas joined Gün + Partners in 2006 and became a partner in 2014. She specializes in life sciences and intellectual property with a special focus on patents and utility models.

Selin has been involved in a number of advisory and litigation matters in all fields of IP and has handled hundreds of contentious and non-contentious administrative oppositions and court actions involving intellectual property rights, particularly in relation with protection of patent rights. She regularly advises on patent infringement actions, declaration of non-infringement actions and nullity actions.

She represents multinational pharmaceutical companies before the Ministry of Health on regulatory issues and examinations.

Selin is the spokesperson for some NGOs in Turkey and in Europe and represents these NGOs before the Turkish Parliament and Turkish Ministries. Delegation of the European Union to Turkey contacts with Selin every year before drafting the IP section of the EU Progress Report of Turkey. Selin also advises commercial counselors of Embassy of U.S.A, the British Embassy, and the Embassy of Switzerland in relation with the IP Law and developments in Turkey.


Practice Areas & Work Department

Intellectual Property

Patent and Utility Models

Life Sciences


Languages

English

Turkish

German


Memberships

International Federation of Intellectual Property Attorneys Turkey (FICPI Turkey), Founder and President

International Federation of Intellectual Property Attorneys (FICPI)

Association Internationale pour la Protection de la Propriété Intellectuelle (AIPPI), Standards and Patents Committee

German Association for the Protection of Intellectual Property (GRUR)

Istanbul Arbitration Center (ISTAC), Intellectual Property Working Commission

Biyobenzer İlaçlar ve Patent Tecavüzü Karinesi

Jeneriklere karşı patent haklarının ileri sürülmesi için açılabilecek davaların öncesinde patent hakkı sahibi esasen karanlıkta ilerler. Çünkü özellikle jenerik ilacın kısa ürün bilgisinin henüz yayınlanmadığı veya patentin ihlal edilip edilmediğinin kısa ürün bilgisinde yer alan sınırlı bilgilerle anlaşılamadığı durumlarda ...

22.10.2024

Applying Presumption of Patent Infingement Against Biosimilars

Before filing lawsuits to assert patent rights against generics or biosimilars, the patent holder essentially operates in the dark.

24.09.2024

Implementation of Discovery of Evidence in Patent Law

One of the most important temporary protection measures regulated by Turkish law is the determination of evidence.

29.08.2024

What Will Be the Fate of the Guarantee Provided for the Preliminary Injunction Decision?

Is the Guarantee Provided for the Preliminary Injunction a Part of the Later Compensation Action Arising from the Unfair Preliminary Injunction?

14.06.2024

Jurisdictional Conflicts in Global FRAND Cases and the EU's WTO Complaint against China for Alleged Violation of TRIPs

Anti-suit injunctions ("ASI") issued by Chinese courts, which prevent parties of proceedings concerning standard-essential patents ("SEPs") from bringing proceedings against each other in different countries, have become one of the controversial issues in these proceedings, highlighting the "jurisdiction of the court".

20.03.2024

Kısmi İhtiyati Tedbir Kararı ile Orijinal İlacın Fiyat Düşüşünün Önlenmesi

Kanunlar ve uluslararası sözleşmeler ile kendilerine tanınmış patent haklarından yararlanmak isteyen ilaç patenti sahiplerinin, bu haklarından sağlıklı bir şekilde yararlanabilmeleri için doğru stratejiyi belirleyerek doğru zamanda doğru adımları atmaları büyük önem arz etmektedir. Zira Sınai Mülkiyet Kanunumuz ile ilaçların ruhsatlandırılması ve bunun için gerekli test ve deneyler de dâhil olmak üzere, patent konusu buluşu içeren deneme amaçlı fiiller patent hakkının istisnalarından bir tanesi olarak düzenlenmiştir.

29.01.2024

Preventing Price Decreases of Original Pharmaceutical Products with Partial Preliminary Injunctions

Taking the right steps at the right time, with the most appropriate strategy, is significantly important for patent owners of pharmaceutical products wishing to benefit from the related rights granted to them by the laws and international conventions. Indeed, the Turkish Industrial Property Code regulates the exception of patent rights concerning experimental acts in regard to the product subject to the invention, as well as marketing authorization, and the necessary testing and experiments within its scope.

23.01.2024

Turning the Turkish Tide on Rising Tactical Patent Invalidation Actions

Filing patent invalidation actions for tactical purposes such as jeopardising patent infringement actions of patent owners and gaining time by complicating the infringement proceedings has become a common strategy of infringers in recent years. This strategy may cause the patent owner to suffer due to the inability to use its patent properly during the limited protection period of 20 years, even if the invalidity claims do not have a solid basis and they are filed on a ‘try your luck’ basis.

07.12.2023
Load More
Ready to stay ahead of the curve?
Share your interest anonymously and let us guide you through the informative articles on the hottest legal topics.
|
Successful Your message has been sent